Announcements

1. "Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets"
by Lokesh Agrawal, Thanasis Poullikkas, Scott Eisenhower, Carlo Monsanto, Ranjith Kumar Bakku, Min-Hua Chen and Rajkumar Singh Kalra
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3

2. "Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System"
by Stefania C. Carrara, David Fiebig, Jan P. Bogen, Julius Grzeschik, Björn Hock and Harald Kolmar
Antibodies 2021, 10(2), 18; https://doi.org/10.3390/antib10020018
Available online: https://www.mdpi.com/2073-4468/10/2/18

3. "Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer"
by Violet Y. Tu, Asma Ayari and Roddy S. O’Connor
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25

4. "Engineered mRNA and the Rise of Next-Generation Antibodies"
by Laura Sanz and Luis Álvarez-Vallina
Antibodies 2021, 10(4), 37; https://doi.org/10.3390/antib10040037
Available online: https://www.mdpi.com/2073-4468/10/4/37

5. "Applications of Antibody-Based Antigen Delivery Targeted to Dendritic Cells In Vivo"
by Jessica Bourque and Daniel Hawiger
Antibodies 2022, 11(1), 8; https://doi.org/10.3390/antib11010008
Available online: https://www.mdpi.com/2073-4468/11/1/8

6. "Strategies to Screen Anti-AQP4 Antibodies from Yeast Surface Display Libraries"
by Aric Huang, Wei Jin, Ahmed S. Fahad, Brooklyn K. Mussman, Grazia Paola Nicchia, Bharat Madan, Matheus Oliveira de Souza, J. Daniel Griffin, Jeffrey L. Bennett, Antonio Frigeri et al.
Antibodies 2022, 11(2), 39; https://doi.org/10.3390/antib11020039
Available online: https://www.mdpi.com/2073-4468/11/2/39

7. "Mitochondrial Autoantibodies and the Role of Apoptosis in Pemphigus Vulgaris"
by Dana M. Hutchison, Anna-Marie Hosking, Ellen M. Hong, and Sergei A. Grando
Antibodies 2022, 11(3), 55; https://doi.org/10.3390/antib11030055
Available online: https://www.mdpi.com/2073-4468/11/3/55

8. "Structural Investigation of Therapeutic Antibodies Using Hydroxyl Radical Protein Footprinting Methods"
by Corie Y. Ralston and Joshua S. Sharp
Antibodies 2022, 11(4), 71; https://doi.org/10.3390/antib11040071
Available online: https://www.mdpi.com/2073-4468/11/4/71

We are pleased to announce the Antibodies Editor's Choice Articles published in 2020 and 2021. Editor’s Choice Articles are selected based on suggestions from the academic editors of Antibodies (ISSN: 2073-4468) from around the world. Editors select a small number of articles recently published in the journal that they consider to be of particular interest to readers or important in their respective fields of research. We are delighted to present the Editor's Choice Articles from 2020 and 2021, a curated list of high-quality articles from Antibodies. The full list of Editor’s Choice Articles can be found at the following link: https://www.mdpi.com/journal/antibodies/editors_choice. 

“Monoclonal Antibodies in Cancer Therapy”
by David Zahavi and Louis Weiner
Antibodies 2020, 9(3), 34; https://doi.org/10.3390/antib9030034
Available online: https://www.mdpi.com/2073-4468/9/3/34
Cited by 147 | Viewed by 17551 

“Antibody Conjugates-Recent Advances and Future Innovations”
by Donmienne Leung, Jacqueline M. Wurst, Tao Liu, Ruben M. Martinez, Amita Datta-Mannan and Yiqing Feng
Antibodies 2020, 9(1), 2; https://doi.org/10.3390/antib9010002
Available online: https://www.mdpi.com/2073-4468/9/1/2
Cited by 51 | Viewed by 12315 

“From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry”
by Darja Kanduc
Antibodies 2020, 9(3), 33; https://doi.org/10.3390/antib9030033
Available online: https://www.mdpi.com/2073-4468/9/3/33
Cited by 48 | Viewed by 12455 

“Structure, Function, and Therapeutic Use of IgM Antibodies”
by Bruce A. Keyt, Ramesh Baliga, Angus M. Sinclair, Stephen F. Carroll and Marvin S. Peterson
Antibodies 2020, 9(4), 53; https://doi.org/10.3390/antib9040053
Available online: https://www.mdpi.com/2073-4468/9/4/53
Cited by 45 | Viewed by 10761 

“Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment”
by Rena Liu, Robert J. Oldham, Emma Teal, Stephen A. Beers and Mark S. Cragg
Antibodies 2020, 9(4), 64; https://doi.org/10.3390/antib9040064
Available online: https://www.mdpi.com/2073-4468/9/4/64
Cited by 42 | Viewed by 11394 

“Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations”
by Souad Boune, Peisheng Hu, Alan L. Epstein and Leslie A. Khawli
Antibodies 2020, 9(2), 22; https://doi.org/10.3390/antib9020022
Available online: https://www.mdpi.com/2073-4468/9/2/22
Cited by 25 | Viewed by 9663 

“Complement System: Promoter or Suppressor of Cancer Progression?”
by Margot Revel, Marie V. Daugan, Catherine Sautés-Fridman, Wolf H. Fridman and Lubka T. Roumenina
Antibodies 2020, 9(4), 57; https://doi.org/10.3390/antib9040057
Available online: https://www.mdpi.com/2073-4468/9/4/57
Cited by 21 | Viewed by 4840 

“A Review of Deep Learning Methods for Antibodies”
by Jordan Graves, Jacob Byerly, Eduardo Priego, Naren Makkapati, S. Vince Parish, Brenda Medellin and Monica Berrondo
Antibodies 2020, 9(2), 12; https://doi.org/10.3390/antib9020012
Available online: https://www.mdpi.com/2073-4468/9/2/12
Cited by 21 | Viewed by 11852 

“Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections”
by Uri Galili
Antibodies 2020, 9(2), 25; https://doi.org/10.3390/antib9020025
Available online: https://www.mdpi.com/2073-4468/9/2/25
Cited by 20 | Viewed by 4329 

“The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs”
by Josée Golay and Ronald P. Taylor
Antibodies 2020, 9(4), 58; https://doi.org/10.3390/antib9040058
Available online: https://www.mdpi.com/2073-4468/9/4/58
Cited by 19 | Viewed by 4898 

“A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation”
by Yutaka Matsuda, Monica Leung, Tatsuya Okuzumi and Brian Mendelsohn
Antibodies 2020, 9(2), 16; https://doi.org/10.3390/antib9020016
Available online: https://www.mdpi.com/2073-4468/9/2/16
Cited by 17 | Viewed by 5788 

“Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease”
by Irina A. Pashnina, Irina M. Krivolapova, Tamara V. Fedotkina, Varvara A. Ryabkova, Margarita V. Chereshneva, Leonid P. Churilov and Valeriy A. Chereshnev
Antibodies 2021, 10(1), 9; https://doi.org/10.3390/antib10010009
Available online: https://www.mdpi.com/2073-4468/10/1/9
Cited by 17 | Viewed by 6924 

“Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19”
by Zheng Cai, Mark I. Greene, Zhiqiang Zhu and Hongtao Zhang
Antibodies 2020, 9(4), 52; https://doi.org/10.3390/antib9040052
Available online: https://www.mdpi.com/2073-4468/9/4/52
Cited by 17 | Viewed by 4795 

“Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents”
by Geert van Tetering, Geert, Mitchell Evers, Chilam Chan, Marjolein Stip and Jeanette Leusen
Antibodies 2020, 9(4), 70; https://doi.org/10.3390/antib9040070
Available online: https://www.mdpi.com/2073-4468/9/4/70
Cited by 14 | Viewed by 4550 

“IgE Antibodies against Cancer: Efficacy and Safety”
by Jitesh Chauhan, Alex J. McCraw, Mano Nakamura, Gabriel Osborn, Heng Sheng Sow, Vivienne F. Cox, Chara Stavraka, Debra H. Josephs, James F. Spicer, Sophia N. Karagiannis et al.
Antibodies 2020, 9(4), 55; https://doi.org/10.3390/antib9040055
Available online: https://www.mdpi.com/2073-4468/9/4/55
Cited by 13 | Viewed by 5176 

“Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer”
by Violet Y. Tu, Asma Ayari and Roddy S. O’Connor
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25
Cited by 12 | Viewed by 4200 

“Utilizing Immunocytokines for Cancer Therapy”
by Erin Runbeck, Silvia Crescioli, Sophia N. Karagiannis and Sophie Papa
Antibodies 2021, 10(1), 10; https://doi.org/10.3390/antib10010010
Available online: https://www.mdpi.com/2073-4468/10/1/10
Cited by 11 | Viewed by 4707 

“Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies”
by Josée Golay and Alain E. Andrea
Antibodies 2020, 9(2), 17; https://doi.org/10.3390/antib9020017
Available online: https://www.mdpi.com/2073-4468/9/2/17
Cited by 10 | Viewed by 5100 

“Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review”
by Mahdi Alsaleem
Antibodies 2020, 9(4), 60; https://doi.org/10.3390/antib9040060
Available online: https://www.mdpi.com/2073-4468/9/4/60
Cited by 10 | Viewed by 5880 

“IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases?”
by Christophe Pellefigues
Antibodies 2020, 9(3), 47; https://doi.org/10.3390/antib9030047
Available online: https://www.mdpi.com/2073-4468/9/3/47
Cited by 10 | Viewed by 3813 

“Antibody Screening by Microarray Technology—Direct Identification of Selective High-Affinity Clones”
by Martin Paul and Michael G. Weller
Antibodies 2020, 9(1), 1; https://doi.org/10.3390/antib9010001
Available online: https://www.mdpi.com/2073-4468/9/1/1
Cited by 9 | Viewed by 5988 

“Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors”
by Vladimir Voynov, Paul J. Adam, Andrew E. Nixon and Justin M. Scheer
Antibodies 2020, 9(4), 65; https://doi.org/10.3390/antib9040065
Available online: https://www.mdpi.com/2073-4468/9/4/65
Cited by 9 | Viewed by 4841 

“Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics”
by Xiaotian Zhong and Aaron M. D’Antona
Antibodies 2021, 10(2), 13; https://doi.org/10.3390/antib10020013
Available online: https://www.mdpi.com/2073-4468/10/2/13
Cited by 9 | Viewed by 5743 

“The Course of SARS-COV2 Infection Was Not Severe in a Crohn’s Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection”
by Francis Okeke, Anjali Mone and Arun Swaminath
Antibodies 2020, 9(3), 42; https://doi.org/10.3390/antib9030042
Available online: https://www.mdpi.com/2073-4468/9/3/42
Cited by 8 | Viewed by 4231 

“Introduction to Antibody-Drug Conjugates”
by Mark C. Pettinato
Antibodies 2021, 10(4), 42; https://doi.org/10.3390/antib10040042
https://www.mdpi.com/2073-4468/10/4/42
Cited by 8 | Viewed by 3767 

“An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer”
by Fazrena Nadia Md Akhir, Mohd Hezmee Mohd Noor, Keith Weng Kit Leong, Jamileh A. Nabizadeh, Helga D. Manthey, Stefan E. Sonderegger, Jenny Nga Ting Fung, Crystal E. McGirr, Ian A. Shiels, Paul C. Mills et al.
Antibodies 2021, 10(1), 2; https://doi.org/10.3390/antib10010002
Available online: https://www.mdpi.com/2073-4468/10/1/2
Cited by 7 | Viewed by 3239 

“From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry”
by Darja Kanduc
Antibodies 2021, 10(4), 36; https://doi.org/10.3390/antib10040036
Available online: https://www.mdpi.com/2073-4468/10/4/36
Cited by 6 | Viewed by 3821 

“Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2”
by Jeffrey V. Leyton
Antibodies 2020, 9(3), 32; https://doi.org/10.3390/antib9030032
https://www.mdpi.com/2073-4468/9/3/32
Cited by 6 | Viewed by 4632 

“HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1”
by Marius Gramlich, Henry C. W. Hays, Scott Crichton, Philipp D. Kaiser, Anne Heine, Nicole Schneiderhan-Marra, Ulrich Rothbauer, Dieter Stoll, Sandra Maier and Anne Zeck
Antibodies 2021, 10(1), 11; https://doi.org/10.3390/antib10010011
Available online: https://www.mdpi.com/2073-4468/10/1/11
Cited by 6 | Viewed by 3507 

“Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective”
by Andrew T. Lucas, Amber Moody, Allison N. Schorzman and William C. Zamboni
Antibodies 2021, 10(3), 30; https://doi.org/10.3390/antib10030030
Available online: https://www.mdpi.com/2073-4468/10/3/30
Cited by 6 | Viewed by 4572 

“Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy”
by Yasmin Jenkins, Joanna Zabkiewicz, Oliver Ottmann and Nicholas Jones
Antibodies 2021, 10(2), 17; https://doi.org/10.3390/antib10020017
Available online: https://www.mdpi.com/2073-4468/10/2/17
Cited by 6 | Viewed by 4406 

“Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets”
by Lokesh Agrawal, Thanasis Poullikkas, Scott Eisenhower, Carlo Monsanto, Ranjith Kumar Bakku, Min-Hua Chen and Rajkumar Singh Kalra
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3
Cited by 5 | Viewed by 5233 

“New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis”
by Roberto Lande, Raffaella Palazzo, Anna Mennella, Immacolata Pietraforte, Marius Cadar, Katia Stefanantoni, Curdin Conrad, Valeria Riccieri and Loredana Frasca
Antibodies 2021, 10(2), 12; https://doi.org/10.3390/antib10020012
Available online: https://www.mdpi.com/2073-4468/10/2/12
Cited by 4 | Viewed by 3213

We are pleased to announce the launch of a new initiative—the MDPI Special Issue Mentor Program.

This program will enable early career researchers (who must hold a Ph.D. in a related field) to experience editing a Special Issue in MDPI journals, under the mentorship of our experienced Editorial Board Members or other experienced scientists. The mentor program will provide an excellent opportunity for early career scientists to gain editorial experience, and to cultivate their ability to edit scientific research.

The mentee’s responsibilities include:

• Proposing a Special Issue title and assisting the mentor in preparing a summary (around 200–400 words) and 3–10 keywords describing the background, importance, and goal of the Issue;
• Writing a brief promotion plan for the Special Issue;
• Preparing a list of scholars who may be interested in the Issue and personally e-mailing invitations on behalf of Guest Editors;
• Writing an editorial for the online Special Issue together with the mentor.

The mentor’s responsibilities include:

• Conducting a final check before the Special Issue is published online;
• Performing editorial control of the Special Issue and quality control of the publications, both of which must be carried out in a timely manner;
• Providing suggestions to younger scholars if they have any doubts or concerns regarding submissions;
• Organizing video calls with young scholars and the Editorial Office regularly to discuss problems and improvement suggestions for the Special Issue;
• Making and submitting decisions regarding submissions with the assistance of mentees.

Certificates and awards:
After the Special Issue closes, the Editorial Office will provide official certificates for all the mentors and early career researchers.

If you are interested in this opportunity, please send your Special Issue proposal to the Editorial Office of a journal you choose, and we will discuss the process (i.e., mentor collaboration, Special Issue topic feasibility analysis, etc.) in further detail. The full list of MDPI journals is as follows: https://www.mdpi.com/about/journals.

In addition to the new Special Issue Mentor Program, we will continue to welcome all Special Issue proposals focusing on hot research topics.

MDPI has just become the first open access (OA) publisher to reach the milestone of one million articles published. That is one million articles freely available to all, to circulate and build upon! We are proud to share this special moment with the global scientific community.

This landmark has been reached thanks to the immeasurable support of more than 600,000 expert reviewers, 66,000 editorial board members and 6700 hard-working colleagues across MDPI’s global offices.

Within more than 25 years of publishing, our journals received 2.1 million manuscripts and generated 4.6 million peer review reports to get to one million papers published.

Reaching the milestone of one million articles published reinforces our mission to remove any existing barriers and to make scientific research accessible to all. Since its inception, MDPI’s goal has been to create reliable processes to make science open. This is a path towards facilitating the dissemination of novel insights in scientific communities.

Regular feedback from authors and reviewers shows that our service is greatly appreciated and needed. At the same time, the feedback helps us identify areas for further improvement.

As it stands, a significant share of published research findings remain closed access. More than half of the content published with the most well-known legacy publishers stays behind a paywall, and that is not including articles published in hybrid OA journals, or made available months or years after publication.

A new policy announced by the US administration in August 2022 requires that, as of January 2026, all US federally funded research be made freely and immediately available after publication. While the new policy does not mandate articles be published under an open access license, it is aligned with the open access movement in removing all barriers to research. Similarly, some of the most advanced research institutions in the world intend to have all funded research articles published in open access by 2025.

MDPI is proud to be the leading agent of the transition to open access.

"Thanks a Million" to all the contributors!

We are pleased to announce that the website of the MDPI Sustainability Foundation has been revamped! For the past couple of months, our UX UI team and front-end developers have been working hard to launch the website in time for the opening of the Sustainability Awards nominations.

The website is not the only thing that has had a remodeling. Indeed, the format of the Emerging Sustainability Leader Award (ESLA) has been updated. ESLA is now a competition open to individual researchers or start-ups founded by researchers under the age of 35. Nominee applications will go through 2 rounds of selection until the final 3 are decided. The finalists will then be invited to give pitch presentations during the Award Ceremony to win either first place (10,000 USD) or runner-up (2 x 5000 USD).

The World Sustainability Award, on the other hand, remains the same: a total prize money of 100,000 USD is up for grabs by senior individual researchers or groups of researchers from the international research community.

Nominations for both the World Sustainability Award and the Emerging Sustainability Leader award are now open! Check out our new website for more information on how to nominate.

Stanford University has recently published an update of the list of the top 2% most widely cited scientists—the World’s Top 2% Scientists.

The time node of the statistical data of this list is from 1960 to 2022, and it is divided into two lists: “Lifetime Scientific Influence Ranking” and “2022 Annual Scientific Influence Ranking”. The “Lifetime Scientific Influence Ranking” measures the comprehensive influence performance of scientists during their careers, and the “2022 Annual Influence Ranking” focuses on highlighting the academic influence of scientists in the previous year. This ranking, considered to be the most prestigious worldwide, is based on the bibliometric information contained in the Scopus database, and includes more than 200,000 researchers from the more than 10 million scientists considered to be active worldwide, with 22 scientific fields and 176 subfields taken into account.

We are pleased to share that 21 Editorial Board Members from MDPI’s Antibodies (ISSN: 2073-4468) were featured in Stanford University’s list of the World’s Top 2% Scientists in 2022.

The latest Stanford rankings reflect the significant influence and research excellence of the above scientists, who are committed to furthering their knowledge for the benefit of the world.

We would like to congratulate our Editorial Board Members on their excellent achievement and thank them for their immense contributions to the scientific progression and development of Antibodies.

Peer Review Week began 19 September 2022 under the theme of “Research Integrity: Creating and Supporting Trust in Research”. Through various blog articles, podcast, and webinar, we discussed this crucial subject throughout the week, celebrating the essential role peer review plays in maintaining research quality.

To begin, we held a Webinar on the topic. Professor Peter W. Choate and Dr. Emmanuel Obeng-Gyasi joined Dr. Ioana Craciun, one of MDPI’s scientific officers, for an in-depth discussion.

We invite you to view the event recording:

During the week, the MDPI Blog in a series articles highlighted how good Peer Review safeguards research integrity. The following topics were covered:

• Peer Review Week 2022
• Research Integrity
• What We’ve Learned About Peer Review Reports
• 4 Steps to the Perfect Peer Review Report
• How to Write the Perfect Peer Review Report: An Interview
• Inviting Great Peer Reviewers

In a new edition of Insight Faster, an MDPI podcast, we were delighted to talk to the co-chairs of the Peer Review Week committee, Jayashree Rajagopalan (Senior Manager of Global Community Engagement for CACTUS) and Danielle Padula (Head of Marketing and Community Development at Scholastica) to get their take on this year’s event and its related topics.

You can find the Podcast here.

We hope you enjoy the contents!

Antibodies (ISSN: 2073-4468) is an international, peer-reviewed open access journal that provides an advanced forum for scientific publications related to antibodies and antigens. The journal is covered by PubMed (NLM), Scopus (Elsevier), Emerging Sources Citation Index (ESCI, Web of Science), and many other databases.

The Antibodies editorial team is pleased to announce this open call for Special Issue proposals, which offers a group of authors the opportunity to work on an interconnected set of papers on an innovative topic. We are soliciting high-quality proposals that will be evaluated in a continuous selection process throughout the year.

Proposals within the scope of the journal are welcome. For more details, please see: https://www.mdpi.com/journal/antibodies/about.

If you would like to propose a Special Issue topic for this journal, please contact the Antibodies Editorial Office (antibodies@mdpi.com) or complete and submit the form at the following link: https://www.mdpi.com/journalproposal/sendproposalspecialissue/antibodies. Our editors will respond to you as soon as possible.

The following information should be featured in the proposal:

• A 150–200-word summary that clearly states the significance, novelty, technical advancement, and adherence of the proposed topic to the scope of the journal;
• A list of 5–10 keywords related to the topic;
• A brief resume of the proposed Guest Editors, together with their information (title, name, email, affiliation, personal website, and keywords of interests);
• A proposed submission deadline (a Special Issue will usually be open for submissions for 6–8 months).

The duties of acting as a Guest Editor are as follows:

• Preparing the Special Issue title, brief summary, and keywords;
• Circulating the Call for Papers for the Special Issue and inviting submissions;
• Pre-screening papers, supervising the entire peer-review process, and making decisions based on the reports we collect;
• Promoting the Special Issue at conferences, on social media, and on other relevant platforms.

The benefits of acting as a Guest Editor are as follows:

• Increased visibility and knowledge of innovations in the field;
• Publishing a paper, free of charge, in the Special Issue;
• Discounts for additional papers you invite;
• If ten or more papers are published in this Special Issue, we will make a Special Issue book and send a hard copy to each Guest Editor.

The Editorial Office will set up the Special Issue’s website, arrange the promotional materials, assist with the invitations for paper contributions, and take care of the administrative tasks associated with peer review (including inviting reviewers, collating reports, contacting authors, and arranging professional production before publication).

Please do not hesitate to contact the Editorial Office (antibodies@mdpi.com) for further details and clarification.

We look forward to receiving your proposals.

Antibodies Editorial Office

1. “Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease”
by Irina A. Pashnina et al.
Antibodies 2021, 10(1), 9; https://doi.org/10.3390/antib10010009
Available online: https://www.mdpi.com/2073-4468/10/1/9

2. “Utilizing Immunocytokines for Cancer Therapy”
by Erin Runbeck et al.
Antibodies 2021, 10(1), 10; https://doi.org/10.3390/antib10010010
Available online: https://www.mdpi.com/2073-4468/10/1/10

3. “Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics”
by Xiaotian Zhong et al.
Antibodies 2021, 10(2), 13; https://doi.org/10.3390/antib10020013
Available online: https://www.mdpi.com/2073-4468/10/2/13

4. “From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry”
by Darja Kanduc
Antibodies 2021, 10(4), 36; https://doi.org/10.3390/antib10040036
Available online: https://www.mdpi.com/2073-4468/10/4/36

5. “Introduction to Antibody-Drug Conjugates.”
by Mark C. Pettinato
Antibodies 2021, 10(4), 42; https://doi.org/10.3390/antib10040042
Available online: https://www.mdpi.com/2073-4468/10/4/42

6. “Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets”
by Lokesh Agrawal et al.
Antibodies 2021, 10(1), 3; https://doi.org/10.3390/antib10010003
Available online: https://www.mdpi.com/2073-4468/10/1/3

7. “HDX-MS for Epitope Characterization of a Therapeutic ANTIBODY Candidate on the Calcium-Binding Protein Annexin-A1”
by Marius Gramlich et al.
Antibodies 2021, 10(1), 11; https://doi.org/10.3390/antib10010011
Available online: https://www.mdpi.com/2073-4468/10/1/11

8. “Beyond the Lactate Paradox: How Lactate and Acidity Impact T Cell Therapies against Cancer”
by Violet Y. Tu et al.
Antibodies 2021, 10(3), 25; https://doi.org/10.3390/antib10030025
Available online: https://www.mdpi.com/2073-4468/10/3/25

9. “An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer”
by Fazrena Nadia Md Akhir et al.
Antibodies 2021, 10(1), 2; https://doi.org/10.3390/antib10010002
Available online: https://www.mdpi.com/2073-4468/10/1/2

10. “Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy”
by Yasmin Jenkins et al.
Antibodies 2021, 10(2), 17; https://doi.org/10.3390/antib10020017
Available online: https://www.mdpi.com/2073-4468/10/2/17

The 2021 citation metrics have been officially released in Scopus!

We are pleased to announce that 182 MDPI journals are included, of which:

● 21 journals received their first CiteScore.
● 85% of journals increased their CiteScore from 2020.
● 155 journals (85%) ranked above average, in at least one category.

The following 65 MDPI journals (36%) ranked among the top 25% of journals, in at least one category:

Source: 2021 CiteScores™ (Elsevier)